Amgen Shows Confidence in Advaxis’ Platform with $540 M Deal

By Dan Roberts

Pharma Deals Review: Vol 2016 Issue 8 (Table of Contents)

Published: 11 Aug-2016

DOI: 10.3833/pdr.v2016.i8.2183     ISSN: 1756-7874

Section: Research & Development



Advaxis has recently announced an agreement with Amgen for the development and commercialisation of its preclinical asset ADXS-NEO (Deal no...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details